New products in the areas of prescription brand and generic drugs, home health care, health and beauty, etc.
Kenwood Therapeutics, Fairfield, N.J., (973) 882-2402, a division of Bradley Pharmaceuticals, has reported the introduction of Peranex HC Cream (hydrocortisone acetate 2%/lidocaine HCl 2%) on behalf of its Kenwood Therapeutics division. This is the first in a new line of anorectal anti-inflammatory and anesthetic products for the relief of itching and painful hemorrhoids, anal fissures, and other conditions of the anal area.
Stiefel Laboratories, Coral Gables, Fla., (888) 784-3335, has received FDA approval for Extina (ketoconazole) Foam 2% for the treatment of seborrheic dermatitis. Its VersaFoam delivery hastens absorption into the skin.
A.T.S. Pharmaceuticals, Los Angeles, (866) 367-8796, a division of Auriga Laboratories, is launching the Xyralid RC (lidocaine HCl 3%/hydrocortisone 1%) rectal cream kit for the treatment of hemorrhoids. The kit contains a seven-day supply of Xyralid Rectal Cream and a seven-day supply of Konsyl, a 100% psyllium laxative.
Rapid-Acting Apidra (insulin glulisine [rDNA origin] injection), from Sanofi-Aventis, Bridgewater, N.J., (908) 243-6000, represents an additional treatment option for hospitalized diabetes patients with high blood sugar who may benefit from intravenous insulin therapy. Apidra was originally approved in 2004 for adult patients with Type 1 or Type 2 diabetes.
NEW DOSAGE STRENGTHS